Meningococcal Vaccines Market Size, Share & Trends Analysis Report By Brand (Menactra, Menveo), By Type, By Serotype, By Age Group, By Sales Channel, By Region, And Segment Forecasts, 2023 - 2030

Research Methodology

A three-pronged approach was followed for deducing the meningococcal vaccines market estimates and forecasts. The process has three steps: information procurement, analysis, and validation. The whole process is cyclical, and steps repeat until the estimates are validated. The three steps are explained in detail below:

Information procurement: Information procurement is one of the most extensive and important stages in our research process, and quality data is critical for accurate analysis. We followed a multi-channel data collection process for meningococcal vaccines market to gather the most reliable and current information possible.

• We buy access to paid databases such as Hoover’s and Factiva for company financials, industry information, white papers, industry journals, SME journals, and more.
• We tap into Grand View’s proprietary database of data points and insights from active and archived monitoring and reporting.
• We conduct primary research with industry experts through questionnaires and one-on-one phone interviews.
• We pull from reliable secondary sources such as white papers and government statistics, published by organizations like WHO, NGOs, World Bank, etc., Key Opinion Leaders (KoL) publications, company filings, investor documents, and more.
• We purchase and review investor analyst reports, broker reports, academic commentary, government quotes, and wealth management publications for insightful third-party perspectives.

Analysis: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilized different methods of meningococcal vaccines market data depending on the type of information we’re trying to uncover in our research.

• Market Research Efforts: Bottom-up Approach for estimating and forecasting demand size and opportunity, top-down Approach for new product forecasting and penetration, and combined approach of both Bottom-up and Top-down for full coverage analysis.

• Value-Chain-Based Sizing & Forecasting: Supply-side estimates for understanding potential revenue through competitive benchmarking, forecasting, and penetration modeling.

• Demand-side estimates for identifying parent and ancillary markets, segment modeling, and heuristic forecasting.

• Qualitative Functional Deployment (QFD) Modelling for market share assessment.

Market formulation and validation: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilize different methods of data analysis depending on the type of information we’re trying to uncover in our research.

• Market Formulation: This step involves the finalization of market numbers. This step on an internal level is designed to manage outputs from the Data Analysis step.

• Data Normalization: The final market estimates and forecasts are then aligned and sent to industry experts, in-panel quality control managers for validation.

• This step also entails the finalization of the report scope and data representation pattern.

• Validation: The process entails multiple levels of validation. All these steps run in parallel, and the study is forwarded for publishing only if all three levels render validated results.

Meningococcal Vaccines Market Categorization:

The meningococcal vaccines market was categorized into six segments, namely type (Bivalent, Quadrivalent), brand (Menactra, Menveo, Nimenrix, Trumenba, Bexsero), serotype (Serotype A, Serotype B, Serotype C, Serotype W-135, Serotype Y), age group (Infants, Children And Adults), sales channels (Private, Public), and regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa).

Segment Market Methodology:

The meningococcal vaccines market was segmented into type, brand, serotype, age group, sales channels, and regions. The demand at a segment level was deduced using a funnel method. Concepts like the TAM, SAM, SOM, etc., were put into practice to understand the demand. We at GVR deploy three methods to deduce market estimates and determine forecasts. These methods are explained below:

Market research approaches: Bottom-up

• Demand estimation of each product across countries/regions summed up to from the total market.

• Variable analysis for demand forecast.

• Demand estimation via analyzing paid database, and company financials either via annual reports or paid database.

• Primary interviews for data revalidation and insight collection.

Market research approaches: Top-down

• Used extensively for new product forecasting or analyzing penetration levels.

• Tool used invoice product flow and penetration models Use of regression multi-variant analysis for forecasting Involves extensive use of paid and public databases.

• Primary interviews and vendor-based primary research for variable impact analysis.

Market research approaches: Combined

• This is the most common method. We apply concepts from both the top-down and bottom-up approaches to arrive at a viable conclusion.

Regional Market Methodology:

The meningococcal vaccines market was analyzed at a regional level. The global was divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, keeping in focus variables like consumption patterns, export-import regulations, consumer expectations, etc. These regions were further divided into fifty countries, namely, the U.S.; Canada; Germany; the UK; France; Italy; Spain; Russia; Belarus; Georgia; Moldova; Denmark; Sweden; Norway; Japan; China; India; Australia; Singapore; South Korea; Thailand; Vietnam; Malaysia; Indonesia; Kazakhstan; Armenia; Azerbaijan; Tajikistan; Turkmenistan; Uzbekistan; Brazil; Mexico; Argentina; Chile; Cuba; Ecuador; Peru; Colombia; Venezuela; Saudi Arabia; South Africa; UAE; Algeria; Egypt; Tunisia; Iran; Turkey; Iraq; Morocco; Kuwait..

All three above-mentioned market research methodologies were applied to arrive at regional-level conclusions. The regions were then summed up to form the global market.

Meningococcal vaccines market companies & financials:

The meningococcal vaccines market was analyzed via companies operating in the sector. Analyzing these companies and cross-referencing them to the demand equation helped us validate our assumptions and conclusions. Key market players analyzed include:

• Sanofi was incorporated in 1994 and is headquartered in France, engaged in the R&D, manufacture, and marketing of therapeutic solutions comprising diabetes, vaccines, innovative drugs, CVDs, internal medicine, primary healthcare, oncology, arthritis, thrombosis, CNS, vaccines, osteoporosis, animal health, and Genzyme. The vaccines segment includes commercial operations of Sanofi vaccines division: Sanofi Pasteur. Every year, 500 million people are immunized with vaccines from Sanofi Pasteur and 2.5 million doses are produced every day. The company has its presence in 90 countries and has 69 manufacturing sites in 32 countries.

• Merck & Co., Inc. is a U.S.-based healthcare solutions provider. It operates through four segments: pharmaceuticals, healthcare services, animal health, and alliances. It offers therapeutic products for asthma, diabetes, CVDs, hepatitis C, HIV infections, osteoporosis, hypertension, fungal & intra-abdominal infections, and fertility issues. It also offers animal healthcare products, such as anthelmintic products and ointments, for acute & chronic otitis. In addition, it offers products to prevent postoperative nausea & vomiting and for the treatment of metastatic small lung cancer, melanoma, measles, rubella, and chickenpox. The company’s immuno-oncology clinical research program currently involves 700+ trials studying Keytruda across various cancers & treatment settings. The company operates in more than 140 countries worldwide.           

• GlaxoSmithKline plc (GSK) is headquartered in the UK and was founded in 2000. The company is engaged in three businesses globally – research, development, and manufacture of innovative pharmaceutical medicines, vaccines, and consumer healthcare products. The company aims to develop high-quality and differentiated products. The pharmaceutical business consists of a broad portfolio of commercially available innovative & established medicines for respiratory issues and HIV. The company’s R&D focuses mainly on the development of recombinant DNA vaccines and adjuvants. The company developed 582 million doses of vaccines at 12 manufacturing sites in 2020. Its consumer healthcare business includes innovative brands that are recommended by experts and preferred by consumers. The company has been in the respiratory disease segment for the past 40 years. They have expanded and strengthened their business by adding medicines containing ICS, LAMA, and LABA.

• Serum Institute of India Pvt. Ltd. was founded in 1966 and is headquartered in India. It is one of the largest vaccine manufacturers in terms of sales and number of doses. Its vaccines are used in approximately 170 countries. The company has manufactured vaccines for various disorders, including Diphtheria, Pertussis, Polio vaccine, BCG, r-Hepatitis B, Rubella, Tetanus, Hib, Measles, and Mumps. In June 2012, the Serum Institute of India acquired Bilthoven Biological from the Government of the Netherlands.

• Pfizer, Inc. is engaged in the discovery, development, manufacture, sales, and distribution of medical products worldwide. Its product range includes medicines, vaccines, and consumer goods. The company offers products for oncology, immunology, cardiology, diabetes & endocrinology, and neurology. Its commercial operations are managed through innovative health and essential health segments. It operates in five sectors: primary care, oncology, animal & consumer healthcare, emerging economies, and nutrition. The company has 64 manufacturing sites globally.

• Walvax Biotechnology Co., Ltd was incorporated in 2001 and is a China-based biopharmaceutical company. It is a leader in vaccine production, engaged in the discovery, development, manufacture, sales, and distribution of products worldwide. Its product range includes quality vaccines and blood products. The company offers products for pneumonia, septicemia, cellulitis, arthritis, and epiglottitis. The company has two independent subsidiaries, Shanghai Zerun Biotechnology Co., Ltd. (Zerun) and Walvax Technical Center, which have expertise in the research and development of novel rDNA vaccines and bacterial vaccines. It operates in 2,400 counties in 31 provinces of China and 16 countries globally. It has three production facilities in China, which can develop 190 million doses annually.     

• Petrovax is a biopharmaceutical company engaged in the research, development, manufacture, sales, and distribution of pharmaceutical products worldwide. It was founded in 1996 and is headquartered in Russia. Its product portfolio includes vaccines, original pharmaceutical products, generic products, and dietary supplements. The company offers products for infectious diseases, pediatrics, immunology therapy, urology, gynecology, preventative vaccination, reproductive health, and CVDs. The company has 25 years of experience in the pharma market, with 20+ patents for different pharmaceutical molecules. The company exports 12 products globally and employed 800 people worldwide as of 2020.

Value chain-based sizing & forecasting

Supply Side Estimates

• Company revenue estimation via referring to annual reports, investor presentations, and Hoover’s.

• Segment revenue determination via variable analysis and penetration modeling.

• Competitive benchmarking to identify market leaders and their collective revenue shares.

• Forecasting via analyzing commercialization rates, pipelines, market initiatives, distribution networks, etc.

Demand side estimates

• Identifying parent markets and ancillary markets

• Segment penetration analysis to obtain pertinent

• revenue/volume

• Heuristic forecasting with the help of subject matter experts

• Forecasting via variable analysis

Meningococcal Vaccines Market Report Objectives:

• Understanding market dynamics (in terms of drivers, restraints, & opportunities) in the countries.

• Understanding trends & variables in the individual countries & their impact on growth and using analytical tools to provide high-level insights into the market dynamics and the associated growth pattern.

• Understanding market estimates and forecasts (with the base year as 2022, historic information from 2018 to 2021, and forecast from 2023 to 2030). Regional estimates & forecasts for each category are available and are summed up to form the global market estimates.

Meningococcal Vaccines Market Report Assumptions:

• The report provides market value for the base year 2022 and a yearly forecast till 2030 in terms of revenue/volume or both. The market for each of the segment outlooks has been provided on region & country basis for the above-mentioned forecast period.

• The key industry dynamics, major technological trends, and application markets are evaluated to understand their impact on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis.

• We have used the bottom-up approach for market sizing, analyzing key regional markets, dynamics, & trends for various products and end-users. The total market has been estimated by integrating the country markets.

• All market estimates and forecasts have been validated through primary interviews with the key industry participants.

• Inflation has not been accounted for to estimate and forecast the market.

• Numbers may not add up due to rounding off.

• Europe consists of EU-8, Central & Eastern Europe, along with the Commonwealth of Independent States (CIS).

• Asia Pacific includes South Asia, East Asia, Southeast Asia, and Oceania (Australia & New Zealand).

• Latin America includes Central American countries and the South American continent

• Middle East includes Western Asia (as assigned by the UN Statistics Division) and the African continent.

Primary Research

GVR strives to procure the latest and unique information for reports directly from industry experts, which gives it a competitive edge. Quality is of utmost importance to us, therefore every year we focus on increasing our experts’ panel. Primary interviews are one of the critical steps in identifying recent market trends and scenarios. This process enables us to justify and validate our market estimates and forecasts to our clients. With more than 8,000 reports in our database, we have connected with some key opinion leaders across various domains, including healthcare, technology, consumer goods, and the chemical sector. Our process starts with identifying the right platform for a particular type of report, i.e., emails, LinkedIn, seminars, or telephonic conversation, as every report is unique and requires a differentiated approach.

We send out questionnaires to different experts from various regions/ countries, which is dependent on the following factors:

• Report/Market scope: If the market study is global, we send questionnaires to industry experts across various regions, including North America, Europe, Asia Pacific, Latin America, and MEA.

• Market Penetration: If the market is driven by technological advancements, population density, disease prevalence, or other factors, we identify experts and send out questionnaires based on region or country dominance.

The time to start receiving responses from industry experts varies based on how niche or well-penetrated the market is. Our reports include a detailed chapter on the KoL opinion section, which helps our clients understand the perspective of experts already in the market space.